Abstract 1944P
Background
T-cell based therapies are currently explored in clinical trials (NCT04044768, NCT01343043) in patients with synovial sarcoma (SySa). These therapies are targeting cancer testis antigens like Melanoma-Associated Antigen 4 (MAGE-A4) or New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1). We explored the molecular epidemiology of these targets using a tissue micro-array (TMA) from clinical SySa samples.
Methods
We created a TMA consisting of 323 cores from 108 clinical samples (≥2 cores/sample) from archival, paraffin-embedded material originating from 91 individual donors. A sarcoma reference pathologist verified the diagnosis of SySa in the donor sample. Most samples (62%) were collected from the primary tumour, 22% and 16% originated from a metastasis or local recurrence. Slides were stained with MAGE-A4 antibody (#82491, dilution 1:100, Cell Signaling) and NY-ESO-1 antibody (clone E978, dilution 1:200, Sigma), during an overnight incubation. Normal human testis tissue was used as a positive control. Expression of each core was scored as an H-score, defined as: (% stained cells at 0 intensity) × 0 + (% stained cells at 1+ intensity) × 1 + (% stained cells at 2+ intensity) × 2 + (% stained cells at 3+ intensity) × 3. The average of the H-scores from the cores corresponding to the same tumour sample was used for subsequent analyses. Expression of the target was defined as an average H-score ≥ 1 and high expression was defined as an average H-score > 100. Kruskal-Wallis test was used for the statistical analyses.
Results
Expression of NY-ESO-1 and MAGE-A4 was found in 50.9% (55/108) and 68.5% (74/108) of TMA samples. High expression was noticed in 20/108 samples (18.5%) for NY-ESO-1 and in 25/108 samples (23.1%) for MAGE-A4. In 77.8% of the samples there is at least one of these cancer testis antigens expressed. There was no correlation between the expression level and disease status at the sampling moment, nor with clinical outcome of the patient. Additionally, there was no correlation between the expression level and the size of the original tumour.
Conclusions
MAGE-A4 and NY-ESO-1 are expressed in a clinically relevant proportion of SySa cases represented in our TMA, this supports the utility of these antigens as targets for novel cell-based therapies in this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15
1930P - phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06)
Presenter: Young Saing Kim
Session: Poster session 15
1931P - Ultra-rare sarcomas have worse survival compared to non-ultra-rare sarcomas: A national cancer registry study
Presenter: MIng-Jing Lee
Session: Poster session 15
1932P - First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
Presenter: Jose Antonio González
Session: Poster session 15
1933P - Perioperative chemotherapy could reduce the risk of recurrence in resected leiomyosarcoma of the vena cava (LMS-VC): A retrospective bi-centric series on 41 patients
Presenter: Thibaud Bertrand
Session: Poster session 15
1934P - Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma
Presenter: Brian Van Tine
Session: Poster session 15
1935P - Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response
Presenter: Wang Xiang-Xu
Session: Poster session 15
1936P - Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
Presenter: Marcus Renner
Session: Poster session 15
1937P - KM-subtraction meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma
Presenter: Qin Jian Low
Session: Poster session 15
1938P - Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)
Presenter: Maria Aguado Sorolla
Session: Poster session 15